PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaAll Plans · Coverage · Medical Policy · Dermatology, Anesthesiology, Pain Management +4 moreMedium impact

Iontophoresis (CPB 0229, reviewed 2026-04-23)

Effective date
Not stated in the notice
Identified
Aug 18, 2026

Summary

Aetna considers iontophoresis medically necessary for delivering local anesthetic before emergent skin puncture or dermatological procedures, for intractable disabling primary focal hyperhidrosis of the axillae, palms or soles when the stated criteria are met, for short-term iontophoretic fentanyl for acute postoperative pain, and for the sweat test by pilocarpine iontophoresis to diagnose cystic fibrosis. The policy lists many other uses as experimental, investigational or unproven, including acetic acid for rotator cuff disease, heel pain and epicondylitis, corticosteroid or NSAID iontophoresis for musculoskeletal disorders, onychomycosis and tinnitus, because of insufficient evidence of its effectiveness. CPT 97033 is covered for iontophoresis only when the selection criteria are met.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01Billing team: Bill CPT 97033 for iontophoresis only for the covered indications in this policy: delivery of local anesthetic before emergent skin puncture or dermatological procedures, intractable disabling primary focal hyperhidrosis of the axillae, palms or soles, or short-term (less than 24 hours) iontophoretic fentanyl for acute postoperative pain in a setting with monitoring capabilities.
02Billing team: For hyperhidrosis, confirm all selection criteria are met before billing: the member is unresponsive to or unable to tolerate oral pharmacotherapy (anti-cholinergics, beta-blockers or benzodiazepines), significant disruption of professional and/or social life has occurred, and topical aluminum chloride or other extra-strength anti-perspirants are ineffective or result in a severe rash.
03Billing team: Use ICD-10 codes G89.12 or G89.18 for iontophoretic fentanyl, and ICD-10 codes L74.510 through L74.519, L74.52 or R61 for hyperhidrosis only when the criteria above are met.
04Billing team: Bill CPT 89230 for the sweat test by pilocarpine iontophoresis only with ICD-10 codes E84.0 through E84.9 or Z13.228.
05Billing team: Do not bill the experimental, investigational or unproven uses listed in this policy, and do not bill HCPCS codes J2787, J3285 or J7686 based on iontophoresis administration, because the policy lists them as not covered for those indications.

Codes mentioned

9703389230J2787J3285J7686G89.12G89.18L74.510L74.519L74.52R61E84.0E84.9Z13.228

Original notice

Iontophoresis (CPB 0229, reviewed 2026-04-23)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account